MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool

摘要: Minimal residual disease (MRD) testing in multiple myeloma is here to stay. Studies show that MRD negativity consistently associated with longer progression-free survival (PFS). It just a matter of time until will become regulatory endpoint for drug approval. Until can happen, more analysis be required define the exact details setting. For example, randomized studies there need amount improvement between experimental arm and control at given time-point obtain accelerated Such efforts are underway. field as whole, important tasks (near) coming future follows: (1) conduct or finalize expanded setting, (2) develop new better assays-both sensitive assays bone marrow aspirates nonbone aspirate-based (eg, blood-based imaging-based assays), (3) design novel clinical formally assess effect decision making. The aim this issue Journal provide deep comprehensive summary latest knowledge field, outline directions.